Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More